|Bid||692.04 x 800|
|Ask||693.10 x 1200|
|Day's Range||687.21 - 706.59|
|52 Week Range||538.01 - 754.67|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||13.66|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||749.04|
Subscribe to Yahoo Finance Plus to view Fair Value for REGN
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent became the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. The FDA evaluated the Dupixent application for prurigo nodularis under Priority Review. Related: Regeneron